Last reviewed · How we verify
CHOP Plus Famotidine
CHOP Plus Famotidine combines cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP chemotherapy) with famotidine, a histamine H2-receptor antagonist, to enhance chemotherapy efficacy and reduce gastric toxicity.
CHOP Plus Famotidine combines cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP chemotherapy) with famotidine, a histamine H2-receptor antagonist, to enhance chemotherapy efficacy and reduce gastric toxicity. Used for Lymphoma (specific subtype under investigation in Phase 3).
At a glance
| Generic name | CHOP Plus Famotidine |
|---|---|
| Also known as | CHOP Plus Famotidine 40 |
| Sponsor | Sherief Abd-Elsalam |
| Drug class | Combination chemotherapy with gastroprotective agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CHOP is a standard multi-agent chemotherapy regimen used in lymphoma treatment that works through DNA alkylation, topoisomerase inhibition, and microtubule disruption. Famotidine is added to reduce chemotherapy-induced gastrointestinal toxicity by suppressing gastric acid production via H2-receptor antagonism, potentially improving tolerability and allowing better chemotherapy delivery.
Approved indications
- Lymphoma (specific subtype under investigation in Phase 3)
Common side effects
- Nausea and vomiting
- Myelosuppression
- Alopecia
- Mucositis
- Infection
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |